keyword
MENU ▼
Read by QxMD icon Read
search

Cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/28102887/clinical-trial-of-nintedanib-in-patients-with-recurrent-or-metastatic-salivary-gland-cancer-of-the-head-and-neck-a-multicenter-phase-2-study-korean-cancer-study-group-hn14-01
#1
Youjin Kim, Su Jin Lee, Ji Yun Lee, Se-Hoon Lee, Jong-Mu Sun, Keunchil Park, Ho Jung An, Jae Yong Cho, Eun Joo Kang, Ha-Young Lee, Jinsoo Kim, Bhumsuk Keam, Hye Ryun Kim, Kyoung Eun Lee, Moon Young Choi, Ki Hyeong Lee, Myung-Ju Ahn
BACKGROUND: Salivary gland cancers (SGCs) are uncommon and account for less than 5% of all head and neck cancers, but they are histologically heterogeneous. No specific therapy, including targeted agents, has consistently improved clinical outcomes in recurrent/metastatic SGC. Recent studies suggest that vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) play important roles in SGC. Nintedanib is a potent small-molecule, triple-receptor tyrosine kinase inhibitor (VEGFR1, VEGFR2, and VEGFR3; fibroblast growth factor receptor 1 [FGFR1], FGFR2, and FGFR3; and PDGFRα and PDGFRß)...
January 19, 2017: Cancer
https://www.readbyqxmd.com/read/28102848/statins-in-anthracycline-induced-cardiotoxicity-rac-and-rho-and-the-heartbreakers
#2
REVIEW
Christian Henninger, Gerhard Fritz
Cancer patients receiving anthracycline-based chemotherapy are at risk to develop life-threatening chronic cardiotoxicity with the pathophysiological mechanism of action not fully understood. Besides the most common hypothesis that anthracycline-induced congestive heart failure (CHF) is mainly caused by generation of reactive oxygen species, recent data point to a critical role of topoisomerase II beta (TOP2B), which is a primary target of anthracycline poisoning, in the pathophysiology of CHF. As the use of the only clinically approved cardioprotectant dexrazoxane has been limited by the FDA in 2011, there is an urgent need for alternative cardioprotective measures...
January 19, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28102711/higher-expression-of-ercc1-may-be-associated-with-resistance-to-adjuvant-platinum-based-chemotherapy-in-gastric-cancer
#3
Jiayi Wan, Lin Chao, Arier C Lee, Qi Chen
Potential predictive biomarker(s) to respond to chemotherapy in gastric cancer are unclear. Excision repair cross-complementing 1 (ERCC1), a DNA repair enzyme, is associated with clinical outcomes in gastric cancer. Here, we investigated the expression of ERCC1 in gastric cancer with platinum-based chemotherapy after surgery, and the association between ERCC1 expression and clinical parameters was analyzed. Our data showed that high levels of ERCC1 expression were positively associated with resistance to platinum-based chemotherapy but not with lymph node metastasis and pathological stage...
January 19, 2017: Cancer Investigation
https://www.readbyqxmd.com/read/28102709/weight-loss-during-initial-chemotherapy-predicts-survival-in-patients-with-advanced-gastric-cancer
#4
Kotoe Takayoshi, Keita Uchino, Masahiro Nakano, Koji Ikejiri, Eishi Baba
BACKGROUND: Patients with advanced gastric cancer (AGC) often suffer weight loss, which can be used to predict prognosis. Few reports have assessed the correlation between weight loss during chemotherapy and survival in patients with AGC. METHODS: Fifty-three patients with histologically proven AGC, who started systemic chemotherapy from September 2010 to March 2014, were retrospectively examined for body weight, inflammatory status, and survival. Correlation analyses were performed between weight change and survival...
January 19, 2017: Nutrition and Cancer
https://www.readbyqxmd.com/read/28102529/recovery-from-chemotherapy-induced-white-matter-changes-in-young-breast-cancer-survivors
#5
Thibo Billiet, Louise Emsell, Mathieu Vandenbulcke, Ronald Peeters, Daan Christiaens, Alexander Leemans, Wim Van Hecke, Ann Smeets, Frederic Amant, Stefan Sunaert, Sabine Deprez
In a previous longitudinal diffusion tensor imaging (DTI) study, we observed cerebral white matter (WM) alterations (reduced fractional anisotropy (FA)) related to decreased cognitive performance 3-5 months after chemotherapy-treatment (t2) when compared to baseline (t1) (Deprez et al. in Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(3), 274-281. doi:10.1200/JCO.2011.36.8571, 2012). The current study investigates the evolution and the nature of these previously observed microstructural changes...
January 19, 2017: Brain Imaging and Behavior
https://www.readbyqxmd.com/read/28102506/a-comparison-of-flt-to-fdg-pet-ct-in-the-early-assessment-of-chemotherapy-response-in-stages-ib-iiia-resectable-nsclc
#6
John P Crandall, Abdel K Tahari, Rosalyn A Juergens, Julie R Brahmer, Charles M Rudin, Giuseppe Esposito, Deepa S Subramaniam, Michael V Knopp, Nathan C Hall, Prateek Gajwani, Jeffrey P Leal, Martin A Lodge, Joo H O, Edward W Gabrielson, Lalitha K Shankar, Richard L Wahl
BACKGROUND: The aim of this study was to compare the percentage change in (18)F-fluorothymidine (FLT) standard uptake value (SUV) between baseline and after one cycle of chemotherapy in patients categorized by RECIST 1.1 computed tomography (CT) as responders or non-responders after two cycles of therapy. Change in (18)F-fluorodeoxyglucose (FDG) uptake was also compared between these time points. Nine patients with newly diagnosed, operable, non-small cell lung cancer (NSCLC) were imaged with FDG positron emission tomography/CT (PET), FLT PET/CT, and CT at baseline, following one cycle of neoadjuvant therapy (75 mg/m(2) docetaxel + 75 mg/m(2) cisplatin), and again after the second cycle of therapy...
December 2017: EJNMMI Research
https://www.readbyqxmd.com/read/28102464/a-phase-i-and-pharmacokinetic-study-of-afilbercept-with-folfiri-comparison-of-chinese-and-caucasian-populations
#7
Jianming Xu, Yingxin Li, Xing Sun, Dongsheng Zhang, Rongrui Liu, Samira Ziti-Ljajic, Dongmei Shi, Fengying Xue, Nathalie Le Bail, Ruihua Xu
Background This study assessed the preliminary safety, pharmacokinetics (PK) and anti-tumor effects of aflibercept in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in Chinese patients with previously-treated advanced solid malignancies. Patients and Methods This open-label single-arm Phase I study conducted at two centers in China included adult (≥18 years) patients with metastatic or unresectable solid malignancies who had received ≥1 prior treatment. Patients received aflibercept 4 mg/kg IV on Day 1 followed by FOLFIRI over Days 1 and 2 every 2 weeks, and were assessed for safety, tumor response, PK parameters and immunogenicity...
January 19, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28102437/a-comparison-of-the-effects-of-medical-qigong-and-standard-exercise-therapy-on-symptoms-and-quality-of-life-in-patients-with-advanced-cancer
#8
B L Vanderbyl, M J Mayer, C Nash, A T Tran, T Windholz, T Swanson, G Kasymjanova, R T Jagoe
PURPOSE: Patients with advanced cancer frequently experience anxiety, depression and poor quality of life (QOL), as well as physical symptoms such as fatigue and weakness. Physical exercise has potential to help control these symptoms but the optimal training prescription is still not clear. We performed a study comparing medical Qigong (QG) and standard endurance and strength training (SET) in patients with advanced stage non-small cell lung (NSCLC) and gastrointestinal (GI) cancers...
January 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28101929/dysgeusia-and-health-related-quality-of-life-of-cancer-patients-receiving-chemotherapy-a-cross-sectional-study
#9
E Ponticelli, M Clari, S Frigerio, A De Clemente, I Bergese, E Scavino, A Bernardini, C Sacerdote
The aim of the study was to evaluate taste disorders in patients receiving chemotherapy and to assess the impact of dysgeusia on patients' health-related quality of life (HRQOL). A total of 289 patients with a diagnosis of malignant solid or haematological cancer undergoing chemotherapy completed a questionnaire assessing dysgeusia and HRQOL. Sixty-four per cent of patients developed dysgeusia after and during chemotherapy. A statistically significant correlation was found between type of cancer and dysgeusia (p = ...
January 19, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28101834/management-of-acute-skin-toxicity-with-hypericum-perforatum-and-neem-oil-during-platinum-based-concurrent-chemo-radiation-in-head-and-neck-cancer-patients
#10
Pierfrancesco Franco, Monica Rampino, Oliviero Ostellino, Marina Schena, Giancarlo Pecorari, Paolo Garzino Demo, Massimo Fasolis, Francesca Arcadipane, Stefania Martini, Chiara Cavallin, Mario Airoldi, Umberto Ricardi
Acute skin toxicity is a frequent finding during combined radiotherapy and chemotherapy in head and neck cancer patients. Its timely and appropriate management is crucial for both oncological results and patient's global quality of life. We herein report clinical data on the use of Hypericum perforatum and neem oil in the treatment of acute skin toxicity during concurrent chemo-radiation for head and neck cancer. A consecutive series of 50 head and neck cancer patients undergoing concomitant radio-chemotherapy with weekly cisplatin was analyzed...
February 2017: Medical Oncology
https://www.readbyqxmd.com/read/28101757/final-report-of-kscc0803-feasibility-study-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer-in-japan
#11
Kazuhito Minami, Masaru Morita, Yasunori Emi, Masahiro Okamoto, Eiji Tanaka, Shigeyuki Nagata, Tetsuo Touyama, Kippei Ohgaki, Takaho Tanaka, Hiroshi Okumura, Toyokuni Suenaga, Shoji Tokunaga, Eiji Oki, Yoshihiro Kakeji, Yoshito Akagi, Hideo Baba, Shoji Natsugoe, Yoshihiko Maehara
BACKGROUND: The impact of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected colon cancer was unclear. We previously planned and conducted a prospective feasibility study (KSCC0803) and reported on the safety of oral capecitabine as adjuvant chemotherapy for Japanese patients with resected stage III colon cancer. The purpose of the current study was to assess the survival results from that study. METHODS: The study subjects were Japanese patients with resected stage III colon cancer...
January 18, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28101677/emesis-and-nausea-related-to-single-agent-trabectedin-in-ovarian-cancer-patients-a-sub-study-of-the-mito15-project
#12
Marilena Di Napoli, Chiara Della Pepa, Laura Arenare, Giovanni Scambia, Domenica Lorusso, Francesco Raspagliesi, Gabriella Ferrandina, Vanda Salutari, Roberto Sorio, Anna Maria Mosconi, Giorgia Mangili, Lucia Borgato, Stefano Lepori, Angela Salvino, Sandro Pignata, Sabrina Chiara Cecere
The MITO 15 was a prospective, single-arm trial, evaluating trabectedin monotherapy in patients with recurrent ovarian cancer (OC) who were BRCA mutation-carriers or had a BRCAness phenotype. It is largely reported that trabectedin may induce nausea and vomiting but the real emetogenic potential of the drug, in the different schedules, has never been fully described; furthermore, OC patients are known to have an enhanced risk of developing nausea and vomiting due to female gender, abdominal spreading of the disease, and major surgery experienced by most of them...
January 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28101492/trends-and-predictors-of-chemotherapy-use-among-thyroid-cancer-patients-in-the-national-cancer-database-2004-2013
#13
Stacey A Fedewa, Ahmedin Jemal, Amy Y Chen
BACKGROUND/AIM: Beginning in 2011, the Food and Drug Administration (FDA) approved the use of multikinase inhibitors (MKIs) for medullary thyroid cancers (MTCs), and in 2013 MKIs were approved for metastatic differentiated thyroid cancers (DTCs). However, little is known about the use of chemotherapy in thyroid cancer patients. Thus, the goal of our study was to describe patterns of chemotherapy use, including MKIs, among DTC and MTC patients in the National Cancer Database (NCDB). METHODS: Chemotherapy use, along with other treatment types (surgery and radiation), was assessed between 2004 and 2013...
December 2016: European Thyroid Journal
https://www.readbyqxmd.com/read/28101359/effect-of-combined-treatment-with-micelle-incorporated-cisplatin-nc-6004-and-s-1-on-human-gastric-cancer-xenografts
#14
Masahisa Kudo, Yoshiyuki Yamamoto, Yoshikatsu Koga, Tetsuya Hamaguchi, Tetsuo Akimoto, Masahiro Yasunaga, Yasuhiro Matsumura
Combination therapy with S-1 and cisplatin (CDDP) is the standard chemotherapy for advanced gastric cancer in Japan; however, its administration requires hospitalization for hydration to prevent nephrotoxicity from CDDP. By contrast, NC-6004 appears to reduce the renal toxicity of CDDP and may be used on an outpatient basis. Thus, the effects of combined treatment with S-1 and NC-6004 were compared with those of S-1 and CDDP in a human gastric cancer model. In vitro cytotoxic effects were investigated in 44As3Luc, MKN45 and MKN74 human gastric cancer cell lines...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28101354/histological-complete-response-in-a-patient-with-advanced-biliary-tract-cancer-treated-by-gemcitabine-cisplatin-s-1-combination-chemotherapy-a-case-report
#15
Tokuhiro Matsubara, Tsutomu Nishida, Yoshito Tomimaru, Masashi Yamamoto, Shiro Hayashi, Sachiko Nakajima, Koji Fukui, Keizo Dono, Shiro Adachi, Tatsuya Ioka, Masashi Kanai, Masami Inada
A 68-year-old woman was referred to our hospital with increased levels of biliary enzymes. On imaging, the patient was diagnosed with unresectable intrahepatic biliary tract cancer (BTC) with invasion of the portal vein and para-aortic lymph node metastasis (cT3N1M1, cStage IVb) and underwent endoscopic biliary drainage for the biliary stricture prior to therapy. The patient was subsequently enrolled in a phase III randomized trial (UMIN000014371/NCT02182778) and randomly assigned to receive gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 or 25 mg/m(2) on day 1 and orally twice daily at a dose of 80 mg/m(2) on days 1-7 every 2 weeks...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28101226/evaluation-of-plasma-microrna-levels-to-predict-insensitivity-of-patients-with-advanced-lung-adenocarcinomas-to-pemetrexed-and-platinum
#16
Jinghua Zhu, Yuhua Qi, Jianzhong Wu, Meiqi Shi, Jifeng Feng, Longbang Chen
Pemetrexed combined with platinum is a first-line therapy used to treat patients with advanced non-small cell lung cancer (NSCLC) that exhibit negative or unknown epidermal growth factor receptor (EGFR) mutational status or anaplastic lymphoma kinase (ALK) rearrangements. Lung adenocarcinoma (LAC) is the primary type of NSCLC. In order to prevent overtreatment, it is necessary to identify patients with LAC who may not benefit from certain chemotherapies. Patients recruited in the present study (n=129) were diagnosed with advanced LAC and received first-line pemetrexed and platinum-based chemotherapy...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28101212/effect-of-oxaliplatin-combined-with-polyenephosphatidylcholine-on-the-proliferation-of-human-gastric-cancer-sgc-7901-cells
#17
Tao Jiang, Hongjun Zhang, Xiguang Liu, Hao Song, Ruyong Yao, Jianbin Li, Yuanyuan Zhao
Oxaliplatin (L-OHP) is a platinum compound that is widely used to treat certain solid tumors, including gastric tumors. L-OHP is an effective anti-cancer treatment; however, its usage increases the probability of patients developing hepatic injury with inflammation, referred to as chemotherapy-associated steatohepatitis. The present study aimed to evaluate the outcome of L-OHP treatment combined with polyenephosphatidylcholine (PPC), a major component of essential phospholipids used to treat steatohepatitis, on SGC-7901 gastric cancer cell proliferation...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28101205/impact-of-microsatellite-status-on-chemotherapy-for-colorectal-cancer-patients-with-kras-or-braf-mutation
#18
Chi-Jung Huang, Shih-Hung Huang, Chih-Cheng Chien, Henry Hsin-Chung Lee, Shung-Haur Yang, Chun-Chao Chang, Chia-Long Lee
KRAS and BRAF mutations are frequently detected in cases of colorectal cancer (CRC). The microsatellite status of patients with CRC and mutated KRAS/BRAF is important when determining cancer therapy. In the present study, the microsatellite status and genetic polymorphisms of KRAS (codons 12 and 13) and BRAF (V600E) were characterized in CRC tissue. The mismatch repair activity and oncogenic potential of KRAS were assessed by immunoblots from two KRAS-mutated CRC cell lines, SW480 and HCT116, with different microsatellite statuses, following treatment with 5-fluorouracil (5-FU) and oxaliplatin...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28101203/short-term-effect-analysis-of-radiofrequency-ablation-combined-chemotherapy-on-middle-and-late-period-non-small-cell-lung-cancer
#19
Shuo Yu, Zhen Zhou Wu, Hong Tao Si, Sai Yang, Guang Mao Liu, Xiao Dong Zhao
In this study, we investigated the effect of radiofrequency ablation (RFA) combined chemotherapy on middle and late period non-small cell lung cancer (NSCLC). In total, 85 cases of middle and late period NSCLC patients were selected, and were randomly divided into the RFA combined chemotherapy group, RFA treatment group and chemotherapy group. After treatment, the three groups were followed up for computed tomography (CT) scan, and were analyzed for the effect of RFA combined chemotherapy on middle and late period NSCLC...
December 2016: Oncology Letters
https://www.readbyqxmd.com/read/28100875/the-role-of-thiol-disulphide-homeostasis-in-anthracycline-associated-cardiac-toxicity
#20
Mustafa Topuz, Omer Şen, Mehmet Kaplan, Oguz Akkus, Ozcan Erel, Mustafa Gur
The aim of the present study was to evaluate whether the baseline thiol/disulfide state can predict the occurrence of anthracycline induced cardiac toxicity. A total of 186 cancer patients receiving anthracycline (doxorubicin)-based chemotherapy were enrolled. All patients underwent 2-dimensional (2D) speckle tracking echocardiography (STE) to determine their left ventricular ejection fraction (LVEF) and blood samples for measuring thiol forms were obtained before treatment and 4 weeks after completion of the chemotherapy...
January 17, 2017: International Heart Journal
keyword
keyword
11110
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"